Limits...
Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.

Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H - BMC Cancer (2009)

Bottom Line: The associations between clinicopathological factors and outcome were analyzed.Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.The results of the present study suggest that topoIIalpha expression is associated with histologically aggressive subtypes and shortened survival.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Otolaryngology, Hirosaki University School of Medicine, Hirosaki, Japan. marucell@hotmail.com

ABSTRACT

Background: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis. Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication. The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland tumors and its biological significance.

Methods: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors). The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma. The associations between clinicopathological factors and outcome were analyzed.

Results: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001). Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.

Conclusion: The results of the present study suggest that topoIIalpha expression is associated with histologically aggressive subtypes and shortened survival. Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma by topoIIαgrotein expression level (low vs. high).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2654461&req=5

Figure 3: Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma by topoIIαgrotein expression level (low vs. high).

Mentions: In order to evaluate the prognostic factors for salivary gland carcinomas, multivariate survival analysis using a Cox proportional hazards regression model was performed, and the expression status of topoIIα protein was identified as the most significant of several clinicopathological factors (p < 0.001) (Table 2). The mortality rate of the low expression group (grade 0 and 1+) was 14.3% (4/28), while that of the high expression group (grade 2+ and 3+) was 69.2% (18/26). The average survival period as determined by the Kaplan-Meier method was 114 months for the low expression group (95% confidence interval: 95–133 months) and 26 months for the high expression group (95% confidence interval: 16–36 months) (Fig. 3); the difference in survival between the groups was statistically significant (p < 0.001).


Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.

Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H - BMC Cancer (2009)

Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma by topoIIαgrotein expression level (low vs. high).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2654461&req=5

Figure 3: Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma by topoIIαgrotein expression level (low vs. high).
Mentions: In order to evaluate the prognostic factors for salivary gland carcinomas, multivariate survival analysis using a Cox proportional hazards regression model was performed, and the expression status of topoIIα protein was identified as the most significant of several clinicopathological factors (p < 0.001) (Table 2). The mortality rate of the low expression group (grade 0 and 1+) was 14.3% (4/28), while that of the high expression group (grade 2+ and 3+) was 69.2% (18/26). The average survival period as determined by the Kaplan-Meier method was 114 months for the low expression group (95% confidence interval: 95–133 months) and 26 months for the high expression group (95% confidence interval: 16–36 months) (Fig. 3); the difference in survival between the groups was statistically significant (p < 0.001).

Bottom Line: The associations between clinicopathological factors and outcome were analyzed.Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.The results of the present study suggest that topoIIalpha expression is associated with histologically aggressive subtypes and shortened survival.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Otolaryngology, Hirosaki University School of Medicine, Hirosaki, Japan. marucell@hotmail.com

ABSTRACT

Background: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis. Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication. The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland tumors and its biological significance.

Methods: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors). The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma. The associations between clinicopathological factors and outcome were analyzed.

Results: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001). Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.

Conclusion: The results of the present study suggest that topoIIalpha expression is associated with histologically aggressive subtypes and shortened survival. Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.

Show MeSH
Related in: MedlinePlus